Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CYH33 in recurrent or persistent gynecologic clear cell carcinoma
jRCT2031210216Phase 2Active, not recruiting
- Sponsor
- Haihe
- Start
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of risovalisib mesylate in clear cell ovarian cancer, fallopian tube clear cell adenocarcinoma and Clear Cell Primary Peritoneal Carcinoma (PPCCC), sponsored by Haihe. Primary endpoint: Objective response rate. Started Sep 2021; status: active, not recruiting.
02
Drugs
risovalisib mesylate
03
Conditions
clear cell ovarian cancerfallopian tube clear cell adenocarcinomaClear Cell Primary Peritoneal Carcinoma (PPCCC)
Beyond the preview
Go deeper on jRCT2031210216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210216.